Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
221 to 240 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R01AI167862 | Dissecting dynamic genetic effects from thymus development to immune-mediated disease | 1 | 2025 |
| R01AR062173 | The IL-23/IL-17 Axis in Inflammatory Arthritis | 1 | 2025 |
| R01CA031845 | Synthetic Studies Related to Cancer Research/Treatment | 1 | 2025 |
| R01CA124515 | Crosstalk between butyrophilins and gamma delta T cells in human cancer | 1 | 2025 |
| R01CA142779 | PD-1/PD-L1 modulation in cancer therapy | 1 | 2025 |
| R01CA148706 | Targeting the colchicine binding site in tubulin for cancer therapy | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA181445 | Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform | 1 | 2025 |
| R01CA197296 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | 1 | 2025 |
| R01CA200994 | A precision medicine basis for estrogen therapy for advanced breast cancer | 1 | 2025 |
| R01CA204484 | Novel Enediyne-Based Antibody-Drug Conjugates for Cancers | 1 | 2025 |
| R01CA218668 | Computational and experimental methods for scalable identification of oncogenic non-coding regions | 1 | 2025 |
| R01CA226909 | Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC | 1 | 2025 |
| R01CA237311 | EPIGENETIC REPROGRAMMING OF T CELL EXHAUSTION TO ENHANCE TUMOR IMMUNOTHERAPY | 1 | 2025 |
| R01CA249062 | Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | 1 | 2025 |
| R01CA262132 | A New Immune Checkpoint Pathway in Human Bladder Cancer | 1 | 2025 |
| R01CA262746 | Molecular Pathogenesis of AF10-Rearranged Leukemias | 1 | 2025 |
| R01CA263079 | Reprogramming myeloid cells to inhibit cancer development | 1 | 2025 |
| R01CA266446 | The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy | 1 | 2025 |
| R01CA271545 | Immunoregulatory role of lung-resident club cell factors in lung cancer | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=12